Safety, Efficacy and Tolerability of Bowel Preparation and Colonoscopy in Patient With CHD, CKD and CLD
1 other identifier
observational
74
1 country
1
Brief Summary
Consecutive eligible patients will be enrolled and written informed consent will be obtained from all participants. Routine blood investigations will be sent. Patients with chronic heart failure will be classified based on ejection fraction into 2 groups (EF \</\> 40%), patients with chronic kidney disease will be classified based on KDIGO classification system into grade I-V. Patients with chronic liver disease will be classified according to the child pugh scoring system into three groups (Child A, B and C). All patients will be undergo bowel preparation under supervision. The patients will be given 10 mg of bisacodyl, the night before colonoscopy. A PEG sachet (137.15 g) containing polyethylene glycol (118 g), sodium chloride (2.93 g), potassium chloride (1.484 g), sodium bicarbonate (3.370 g), and anhydrous sodium sulfate (11.36 g) will be constituted into 2 L solution and used for bowel preparation. Patients will receive 1 L of PEG solution between 10 PM and 11 PM the day before and 1 L of PEG solution between 6 AM and 7 AM on the day of colonoscopy. Clear liquids will be allowed after the completion of the last bowel preparation until the start of the procedure. Liquid diet includes soups, fruit juices, rice kanji, or porridge in liquid consistency, and clear liquids such as coconut water and lemon juice. After the adequacy of bowel preparation is deemed fit, the patients will be taken for colonoscopic examination. A single blinded outcome assessment will be done by the colonoscopist/endoscopist performing the procedure (adequacy of bowel preparation) and the endoscopy nurse (tolerability and compliance). Colonoscopy will be performed using standard video colonoscopes (Olympus, Tokyo, Japan) between 11:00 AM and 1:00 PM without sedation. The colonoscopist / endoscopist will assess the adequacy of bowel preparation using the Boston Bowel Preparation Scale (BBPS). Excellent, good and poor bowel preparations will be defined by BBPS score of 9, 6 - 9 and \< 6, respectively. (12-14) Blood sampling will be done before bowel preparation and after colonoscopy in all patients for measurement of baseline parameters, renal function status (Serum creatinine, serum urea), serum electrolytess (serum sodium, serum potassium, serum phosphate and serum calcium) and haematocrit. Assessment of safety and tolerability will be performed using clinical examination and symptom questionnaire. Cardiovascular and gastrointestinal (GI) symptoms will be recorded. Cardiovascular symptoms such as dyspnea, palpitations, chest pain, will be recorded and scored using the NYHA classification system for symptom severity. Clinical examination will be carried out post-bowel preparation and post-procedure to assess for signs of fluid overload, i.e. auscultation for crepitations and measurement of JVP. GI symptoms such as nausea, abdominal pain, vomiting, dizziness, bloating, and headache will be recorded and scored on a 4-point scale: 1 = none, 2 = mild, 3 = moderate, and 4 = severe. The compliance of bowel preparation will be defined as "poor" for patients who consume less than 75% of the PEG preparation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 10, 2024
CompletedFirst Submitted
Initial submission to the registry
February 22, 2025
CompletedFirst Posted
Study publicly available on registry
March 13, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2025
CompletedMarch 13, 2025
February 1, 2025
8 months
February 22, 2025
March 11, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
To check the large intestine
to clear the contents in intestine like faces in gm/dl
60 minutes
Interventions
Colonoscopy is a procedure to see the ascending, transverse, decending, sigmoid, rectum of colon parts
Eligibility Criteria
74 subjects
You may qualify if:
- Adult \>18 years
- Diagnosed cases of chronic heart disease, chronic kidney disease or chronic liver failure planned for elective colonoscopy
You may not qualify if:
- Age \< 18 years
- Current or past history of bowel obstruction or resection
- Known allergies to PEG
- Emergency colonoscopies.
- Pregnant or lactating women
- Paralytic ileus / Bowel perforation
- Inability to protect airway
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Asian Institute of Gastroenterology/AIG Hospitals
Hyderabad, Telangana, 500082, India
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Manohar Dr Reddy, MBBS MD
AIG Hospitals
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
February 22, 2025
First Posted
March 13, 2025
Study Start
August 10, 2024
Primary Completion
March 25, 2025
Study Completion
May 30, 2025
Last Updated
March 13, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share